Goldline Pharmaceutical SME IPO Details
All About Goldline Pharmaceutical:
The Goldline Pharmaceutical size is ₹12 crore, including a fresh issue of ₹12 crore. It is a Bookbuilding issue. The IPO issue opens on May 12, 2026 and closes on May 14, 2026. The share allotment is expected on May 15, 2026, and the listing date is May 19, 2026. Goldline Pharmaceutical is based in Nagpur, Maharashtra and operates in the Pharmaceuticals sector. It filed its DRHP on September 30, 2025 and will list its shares on the BSE SME. Bigshare Services Pvt.Ltd. is the registrar, while Cumulative Capital Pvt.Ltd. serves as the merchant banker for the offer.
IPO Highlights
IPO Reservation and Lot Size
The company has reserved shares for various investor categories. The Retail Shares reservation is 33.33% (9,00,000 shares), and QIB has 47.11% (12,72,000 shares). Further, the minimum lot size is 3,000 shares. The anchor investor reservation is 27.11% (7,32,000 shares), and the market maker reservation is 5.11% (1,38,000 shares).
IPO Issue Structure
QIB | 12,72,000 |
| Anchor Investor | 7,32,000 |
| QIB (Ex. Anchor) | 5,40,000 |
NII (HNI) | 3,90,000 |
| bNII > ₹10L | |
| sNII < ₹10L | |
Retail | 9,00,000 |
Market Maker | 1,38,000 |
Total | 27,00,000 |
On September 30, 2025 the company filed its Draft Red Herring Prospectus. The Red Herring Prospectus is available to understand the business operations, financials, and the risks involved.
IPO GMP
The Grey Market Premium indicates the extra price that people pay in the unofficial market. This value changes daily based on demand for the shares. Track live GMP Today here.
Financial Performance (₹ in Cr)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Total Income | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.83 | 1.81 | 0.26 |
| EBITDA | 5.83 | 4.3 | 2.19 |
| Net Worth | 10.35 | 7.87 | 5.89 |
| Assets | 26.28 | 22.93 | 19.38 |
| Total Debt | 11.03 | 11.13 | 10.82 |
| PAT | 2.83 | 1.81 | 0.26 |
Key Performance Indicator
| Particulars | FY25 | FY24 | FY23 |
|---|---|---|---|
| EBITDA Margin (%) | 20.78 | 18.24 | 11.03 |
| PAT Margin (%) | 10.09 | 7.68 | 1.31 |
| EPS (₹) | 4.11 | 3.01 | 0.43 |
| ROE (%) | 27.34 | 23 | 4.41 |
| ROCE (%) | 38.46 | 32.41 | 19.43 |
| ROA (%) | 10.77 | 7.89 | 1.34 |
| Debt to Equity (x) | 1.07 | 1.41 | 1.84 |
To understand the above financial ratios / financial performance metrics as per the Draft Red Herring Prospectus.
Goldline Pharmaceutical SME IPO Review
You must assess the company’s financial position before deciding on investments. You can read our full review article here.
Disclaimer: The information provided on this website is for general informational purposes only. Before making any investment decisions, you must consult with a qualified financial adviser.
IPO Financial Snapshot
✅Strengths
⚠️Weaknesses
Listing Day TradingBSE SME
Quick Links
Goldline Pharmaceutical Company Details
Goldline Pharmaceutical started its business in –. The company operates in the pharmaceutical sector. It manufactures pharmaceutical products for the Indian market. The team provides marketing and distribution of generic drugs to clients across multiple states. Its main office is in Nagpur. The company markets and sells a wide range of generic pharmaceutical products under the ‘Goldline’ brand name. It follows an asset-light model by partnering with third-party manufacturers.
Main Offerings:
Key Strength:
Company Address: 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015
You can contact the company via call or email.
+91 712 2786666 | info@goldlinepharma.in
Intermediaries & Key Contacts
Frequently Asked Questions
Goldline Pharmaceutical IPO is a BSE SME issue. It comprises a fresh issue of 27,00,000 equity shares of total up to ₹12 crores. The company works in the pharmaceutical sector.
The price band for the IPO is fixed at ₹41 to ₹43 per equity share. The face value is ₹10 per share.
The minimum lot size for this IPO is 3,000 shares. A retail investor needs to invest a minimum of ₹1,29,000 (at the upper price band) for one lot.
The shares allotment is expected to be finalized on May 15, 2026. You can check the status on the registrar’s website.
The shares are tentatively scheduled to be listed on BSE SME on May 19, 2026.
Bigshare Services Pvt.Ltd. is the official registrar for this public issue.
No comments yet. Be the first to share your thoughts!